Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RXFP3 | Q9NSD7 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157546 | 0.88 | HPGD (0.50) | SMN1; SMN2EGLN1HTT | |
| SCHEMBL6162343 | 0.88 | S1PR5 (0.52) | SMN1; SMN2ALDH1A1L3MBTL1EGLN1CYP3A4 | |
| SCHEMBL6157539 | 0.88 | HPGD (0.50) | SMN1; SMN2EGLN1HTT | |
| SCHEMBL6159065 | 0.88 | HPGD (0.50) | SMN1; SMN2EGLN1HTT | |
| SCHEMBL6162336 | 0.88 | S1PR5 (0.52) | SMN1; SMN2ALDH1A1L3MBTL1EGLN1CYP3A4 | |
| SCHEMBL6161609 | 0.86 | HTT (0.58) | SMN1; SMN2ALDH1A1CYP3A4CYP2C19HTT | |
| Hydrochloric Acid SCHEMBL6159995 | 0.85 | APEX1 (0.42) | SMN1; SMN2ALDH1A1L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL6158771 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1HSD17B10L3MBTL1EGLN1 | |
| SCHEMBL6158563 | 0.83 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL6158475 | 0.82 | TDP1 (0.55) | SMN1; SMN2ALDH1A1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924292-B2 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| US-6699881-B2 | MATRIX METALLOPROTEASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030078253-A1 | Thiol compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1270577-A1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078253-A1 | Thiol compounds, their production and use | TST, QSOX1, SULT1E1 | SMN1; SMN2 3819/4885ALDH1A1 905/4885HSD17B10 520/4885 |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | PDE3B, PDE5A, PDE3A | SMN1; SMN2 4678/4885ALDH1A1 572/4885HSD17B10 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.